BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

Market Cap	28.16B +85.0%
Revenue (ttm)	1.30B +9.1%
Net Income	50.85M -63.2%
EPS	0.12 -63.7%
Shares Out	422.54M
PE Ratio	553.77
Forward PE	n/a
Dividend	0.02 (0.02%)
Ex-Dividend Date	Jun 23, 2025

Volume	14,021,420
Average Volume	16,205,046
Open	68.50
Previous Close	68.56
Day's Range	66.13 - 69.00
52-Week Range	38.89 - 122.59
Beta	0.35
RSI	67.10
Earnings Date	Apr 30, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,196
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688166

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 54.51 million, a decrease of -71.18%.